Circ_0026579 knockdown ameliorates lipopolysaccharide-induced human lung fibroblast cell injury by regulating CXCR1 via miR-370-3p
Clin Exp Pharmacol Physiol. 2023 Oct 2. doi: 10.1111/1440-1681.13826. Online ahead of print.ABSTRACTPneumonia is an inflammatory disease in lower respiratory tracts and its development involves the regulation of RNAs. Circular RNAs are a class of RNA subgroups that can mediate the progression of pneumonia. However, the molecular mechanism of circ_0026579 in regulating pneumonia occurrence remains unclear. The study is designed to reveal the role of circ_0026579 in lipopolysaccharide (LPS)-induced human lung fibroblast cell injury and the underlying mechanism. The expression levels of circ_0026579, miR-370-3p and C-X-C moti...
Source: Clinical and Experimental Pharmacology and Physiology - October 3, 2023 Category: Drugs & Pharmacology Authors: Yuanhong Zhuang Yuyun Yang Lihong Peng Source Type: research

Circ_0026579 knockdown ameliorates lipopolysaccharide-induced human lung fibroblast cell injury by regulating CXCR1 via miR-370-3p
Clin Exp Pharmacol Physiol. 2023 Oct 2. doi: 10.1111/1440-1681.13826. Online ahead of print.ABSTRACTPneumonia is an inflammatory disease in lower respiratory tracts and its development involves the regulation of RNAs. Circular RNAs are a class of RNA subgroups that can mediate the progression of pneumonia. However, the molecular mechanism of circ_0026579 in regulating pneumonia occurrence remains unclear. The study is designed to reveal the role of circ_0026579 in lipopolysaccharide (LPS)-induced human lung fibroblast cell injury and the underlying mechanism. The expression levels of circ_0026579, miR-370-3p and C-X-C moti...
Source: Clinical and Experimental Pharmacology and Physiology - October 3, 2023 Category: Drugs & Pharmacology Authors: Yuanhong Zhuang Yuyun Yang Lihong Peng Source Type: research

Circ_0026579 knockdown ameliorates lipopolysaccharide-induced human lung fibroblast cell injury by regulating CXCR1 via miR-370-3p
Clin Exp Pharmacol Physiol. 2023 Oct 2. doi: 10.1111/1440-1681.13826. Online ahead of print.ABSTRACTPneumonia is an inflammatory disease in lower respiratory tracts and its development involves the regulation of RNAs. Circular RNAs are a class of RNA subgroups that can mediate the progression of pneumonia. However, the molecular mechanism of circ_0026579 in regulating pneumonia occurrence remains unclear. The study is designed to reveal the role of circ_0026579 in lipopolysaccharide (LPS)-induced human lung fibroblast cell injury and the underlying mechanism. The expression levels of circ_0026579, miR-370-3p and C-X-C moti...
Source: Clinical and Experimental Pharmacology and Physiology - October 3, 2023 Category: Drugs & Pharmacology Authors: Yuanhong Zhuang Yuyun Yang Lihong Peng Source Type: research

Circ_0026579 knockdown ameliorates lipopolysaccharide-induced human lung fibroblast cell injury by regulating CXCR1 via miR-370-3p
Clin Exp Pharmacol Physiol. 2023 Oct 2. doi: 10.1111/1440-1681.13826. Online ahead of print.ABSTRACTPneumonia is an inflammatory disease in lower respiratory tracts and its development involves the regulation of RNAs. Circular RNAs are a class of RNA subgroups that can mediate the progression of pneumonia. However, the molecular mechanism of circ_0026579 in regulating pneumonia occurrence remains unclear. The study is designed to reveal the role of circ_0026579 in lipopolysaccharide (LPS)-induced human lung fibroblast cell injury and the underlying mechanism. The expression levels of circ_0026579, miR-370-3p and C-X-C moti...
Source: Clinical and Experimental Pharmacology and Physiology - October 3, 2023 Category: Drugs & Pharmacology Authors: Yuanhong Zhuang Yuyun Yang Lihong Peng Source Type: research

Circ_0026579 knockdown ameliorates lipopolysaccharide-induced human lung fibroblast cell injury by regulating CXCR1 via miR-370-3p
Clin Exp Pharmacol Physiol. 2023 Oct 2. doi: 10.1111/1440-1681.13826. Online ahead of print.ABSTRACTPneumonia is an inflammatory disease in lower respiratory tracts and its development involves the regulation of RNAs. Circular RNAs are a class of RNA subgroups that can mediate the progression of pneumonia. However, the molecular mechanism of circ_0026579 in regulating pneumonia occurrence remains unclear. The study is designed to reveal the role of circ_0026579 in lipopolysaccharide (LPS)-induced human lung fibroblast cell injury and the underlying mechanism. The expression levels of circ_0026579, miR-370-3p and C-X-C moti...
Source: Clinical and Experimental Pharmacology and Physiology - October 3, 2023 Category: Drugs & Pharmacology Authors: Yuanhong Zhuang Yuyun Yang Lihong Peng Source Type: research

Monocarboxylate transporter 4 protects against myocardial ischemia/reperfusion injury by inducing oxidative phosphorylation/glycolysis interconversion and inhibiting oxidative stress
Clin Exp Pharmacol Physiol. 2023 Sep 28. doi: 10.1111/1440-1681.13821. Online ahead of print.ABSTRACTMyocardial ischemia/reperfusion (I/R) injury is the primary cause of heart damage in the treatment of myocardial infarction, and the imbalance of the energy metabolism in the pathogenesis of myocardial I/R is one of the main triggers of cardiac dysfunction. Monocarboxylate transporter 4 (MCT4) is a key transporter of lactate, which plays a vital role in cellular metabolism. The present study investigated the role and underlying mechanism of MCT4 in myocardial I/R injury. The results of this study showed that MCT4 was upregu...
Source: Clinical and Experimental Pharmacology and Physiology - September 29, 2023 Category: Drugs & Pharmacology Authors: Qiao Pan Xiaobo Xie Qingxia Yuan Source Type: research

Monocarboxylate transporter 4 protects against myocardial ischemia/reperfusion injury by inducing oxidative phosphorylation/glycolysis interconversion and inhibiting oxidative stress
Clin Exp Pharmacol Physiol. 2023 Sep 28. doi: 10.1111/1440-1681.13821. Online ahead of print.ABSTRACTMyocardial ischemia/reperfusion (I/R) injury is the primary cause of heart damage in the treatment of myocardial infarction, and the imbalance of the energy metabolism in the pathogenesis of myocardial I/R is one of the main triggers of cardiac dysfunction. Monocarboxylate transporter 4 (MCT4) is a key transporter of lactate, which plays a vital role in cellular metabolism. The present study investigated the role and underlying mechanism of MCT4 in myocardial I/R injury. The results of this study showed that MCT4 was upregu...
Source: Clinical and Experimental Pharmacology and Physiology - September 29, 2023 Category: Drugs & Pharmacology Authors: Qiao Pan Xiaobo Xie Qingxia Yuan Source Type: research

Monocarboxylate transporter 4 protects against myocardial ischemia/reperfusion injury by inducing oxidative phosphorylation/glycolysis interconversion and inhibiting oxidative stress
Clin Exp Pharmacol Physiol. 2023 Sep 28. doi: 10.1111/1440-1681.13821. Online ahead of print.ABSTRACTMyocardial ischemia/reperfusion (I/R) injury is the primary cause of heart damage in the treatment of myocardial infarction, and the imbalance of the energy metabolism in the pathogenesis of myocardial I/R is one of the main triggers of cardiac dysfunction. Monocarboxylate transporter 4 (MCT4) is a key transporter of lactate, which plays a vital role in cellular metabolism. The present study investigated the role and underlying mechanism of MCT4 in myocardial I/R injury. The results of this study showed that MCT4 was upregu...
Source: Clinical and Experimental Pharmacology and Physiology - September 29, 2023 Category: Drugs & Pharmacology Authors: Qiao Pan Xiaobo Xie Qingxia Yuan Source Type: research

Monocarboxylate transporter 4 protects against myocardial ischemia/reperfusion injury by inducing oxidative phosphorylation/glycolysis interconversion and inhibiting oxidative stress
Clin Exp Pharmacol Physiol. 2023 Sep 28. doi: 10.1111/1440-1681.13821. Online ahead of print.ABSTRACTMyocardial ischemia/reperfusion (I/R) injury is the primary cause of heart damage in the treatment of myocardial infarction, and the imbalance of the energy metabolism in the pathogenesis of myocardial I/R is one of the main triggers of cardiac dysfunction. Monocarboxylate transporter 4 (MCT4) is a key transporter of lactate, which plays a vital role in cellular metabolism. The present study investigated the role and underlying mechanism of MCT4 in myocardial I/R injury. The results of this study showed that MCT4 was upregu...
Source: Clinical and Experimental Pharmacology and Physiology - September 29, 2023 Category: Drugs & Pharmacology Authors: Qiao Pan Xiaobo Xie Qingxia Yuan Source Type: research

RAD140 (Testolone) negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice
In conclusion, long-term RAD140 supplementation reduced indices of overall health and failed to improve strength in female mice, suggesting that RAD140 (at a 5mg/kg dosage) may be more detrimental than beneficial in delaying or preventing sarcopenia.PMID:37758180 | DOI:10.1111/1440-1681.13824 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - September 27, 2023 Category: Drugs & Pharmacology Authors: Austin M Brown Muni Swamy Ganjayi Cory W Baumann Source Type: research

RAD140 (Testolone) negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice
In conclusion, long-term RAD140 supplementation reduced indices of overall health and failed to improve strength in female mice, suggesting that RAD140 (at a 5mg/kg dosage) may be more detrimental than beneficial in delaying or preventing sarcopenia.PMID:37758180 | DOI:10.1111/1440-1681.13824 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - September 27, 2023 Category: Drugs & Pharmacology Authors: Austin M Brown Muni Swamy Ganjayi Cory W Baumann Source Type: research

Pharmacodynamic study of chitosan in combination with salvianolic acid B in the treatment of CC1 < sub > 4 < /sub > -induced liver fibrosis in mice
In this study, the therapeutic effect of chitosan in combination with salvianolic acid B on liver fibrosis was investigated in a mouse liver fibrosis model. The results showed that the combination of chitosan and salvianolic acid B was better than the drug alone, improving AST/ALT levels and reducing the expression of α-SAM, COL I, IL-6 and other related genes. It improved the structure of gut microbiota and increased the abundance of beneficial bacteria such as Lactobacillus. The above results could provide new ideas for the clinical treatment of liver fibrosis.PMID:37749921 | DOI:10.1111/1440-1681.13828 (Source: Clinica...
Source: Clinical and Experimental Pharmacology and Physiology - September 26, 2023 Category: Drugs & Pharmacology Authors: Zhongwei Yao Minshu Du Yalu Wang He Zhu Luan Shu Xia You Jing Wang Source Type: research

Growth hormone-releasing hormone beyond cancer
Clin Exp Pharmacol Physiol. 2023 Sep 26. doi: 10.1111/1440-1681.13829. Online ahead of print.NO ABSTRACTPMID:37750473 | DOI:10.1111/1440-1681.13829 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - September 26, 2023 Category: Drugs & Pharmacology Authors: Nektarios Barabutis Saikat Fakir Source Type: research

Pharmacodynamic study of chitosan in combination with salvianolic acid B in the treatment of CC1 < sub > 4 < /sub > -induced liver fibrosis in mice
In this study, the therapeutic effect of chitosan in combination with salvianolic acid B on liver fibrosis was investigated in a mouse liver fibrosis model. The results showed that the combination of chitosan and salvianolic acid B was better than the drug alone, improving AST/ALT levels and reducing the expression of α-SAM, COL I, IL-6 and other related genes. It improved the structure of gut microbiota and increased the abundance of beneficial bacteria such as Lactobacillus. The above results could provide new ideas for the clinical treatment of liver fibrosis.PMID:37749921 | DOI:10.1111/1440-1681.13828 (Source: Clinica...
Source: Clinical and Experimental Pharmacology and Physiology - September 26, 2023 Category: Drugs & Pharmacology Authors: Zhongwei Yao Minshu Du Yalu Wang He Zhu Luan Shu Xia You Jing Wang Source Type: research

Growth hormone-releasing hormone beyond cancer
Clin Exp Pharmacol Physiol. 2023 Sep 26. doi: 10.1111/1440-1681.13829. Online ahead of print.NO ABSTRACTPMID:37750473 | DOI:10.1111/1440-1681.13829 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - September 26, 2023 Category: Drugs & Pharmacology Authors: Nektarios Barabutis Saikat Fakir Source Type: research